Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Breakthrough of Global Significance in Detection of Blood Clots

10.07.2003


Agenix Limited [ASX:AGX, NASDAQ: AGXLY] today announced it had made a significant breakthrough in the detection of blood clots at Royal Brisbane Hospital.



Agenix’s blood clot imaging agent ThromboView® successfully detected a Deep Vein Thrombosis (blood clot in the leg) of a patient as part of a Phase 1b clinical trial.

"This is a very pleasing result," said Dr David Macfarlane, co-investigator of the ThromboView® trial. "The medical world has been eagerly seeking a better method to detect blood clots accurately."


"This is a big moment for our company, and we anticipate filing an Investigational New Drug application with the US Food & Drug Administration and initiation of Phase II clinical trials in North America in early 2004," said Don Home, Managing Director of Agenix.

The trial has successfully advanced the clinical development of ThromboViewâ. In a parallel clinical Phase 1a trial, in healthy volunteers, completed several weeks ago, ThromboViewâ was shown to date to be safe and well tolerated.

The current patient-based Phase 1b trial was initiated at Royal Brisbane Hospital and was overseen by Dr. Macfarlane. The study is designed to determine the safety and tolerability of ThromboViewâ in patients with blood clots and will also give an indication of the agent’s ability to assist doctors detect and image blood clots. In both the healthy volunteer trial and in the first patient included in the new trial, the performance of ThromboViewâ continues to meet expectations.

"Previously, ThromboViewâ has been injected into healthy volunteers," said Dr Macfarlane. "Today we are able to announce that ThromboViewâ was not only well tolerated in the patient with the DVT, but that it detected the presence of the DVT in the patient’s leg."

The current trial is anticipated to enroll patients with confirmed Deep Vein Thrombosis at four Australian sites - at Westmead and St George Hospitals in Sydney, at Melbourne’s Austin Repatriation Hospital and at the Royal Brisbane Hospital.

The clinical results of ThromboViewâ to date have been consistent with Agenix’s preclinical studies in which human clots where imaged in animal models.

"We know around 60,000 people die from blood clots in the United States each year, which
makes this a more common cause of death than breast cancer. A similar number each year die from blood clots in Europe," said Mr Home. "Additionally, two million people in both Europe and the USA suffer deep vein thrombosis each year. Thromboembolism is the third most common cause of cardiovascular death after heart attack and stroke."

"It is estimated that up to 10,000 people die of undetected blood clots each year in Australia. There are approximately 33,000 cases of Deep Vein Thrombosis each year in Australia and 4,200 cases of pulmonary embolism (clots in the lungs). "

"Today’s trial commencement is a major step in the development of a breakthrough test to diagnose blood clots early and accurately. Following this trial, we will embark upon further Phase II human trials to confirm efficacy. ThromboViewâ will be rigorously studied. Thrombosis experts are helping us design our clinical trials to maximise our competitive edge and deliver a truly competitive product to market."

ThromboViewâ uses a clot-binding monoclonal antibody attached to a radiolabel. Following injection of a few millilitres of ThromboViewâ into a patient with a suspected blood clot, the antibody will flow through a person’s body and bind to any existing blood clots. The resulting "hotspots", indicating the presence of the blood clot, will be picked up by an imaging camera.

For more information contact:

Mr Don Home
Managing Director
Imaging
Agenix Limited
Ph: 61 7 3370 6300

Ms Sue Parry-Jones
Vice President - Molecular Diagnostic
Agenix Limited
Ph: 61 7 3370

| Agenix Limited
Further information:
http://www.agenix.net

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The spin state story: Observation of the quantum spin liquid state in novel material

New insight into the spin behavior in an exotic state of matter puts us closer to next-generation spintronic devices

Aside from the deep understanding of the natural world that quantum physics theory offers, scientists worldwide are working tirelessly to bring forth a...

Im Focus: Excitation of robust materials

Kiel physics team observed extremely fast electronic changes in real time in a special material class

In physics, they are currently the subject of intensive research; in electronics, they could enable completely new functions. So-called topological materials...

Im Focus: Electrons in the fast lane

Solar cells based on perovskite compounds could soon make electricity generation from sunlight even more efficient and cheaper. The laboratory efficiency of these perovskite solar cells already exceeds that of the well-known silicon solar cells. An international team led by Stefan Weber from the Max Planck Institute for Polymer Research (MPI-P) in Mainz has found microscopic structures in perovskite crystals that can guide the charge transport in the solar cell. Clever alignment of these "electron highways" could make perovskite solar cells even more powerful.

Solar cells convert sunlight into electricity. During this process, the electrons of the material inside the cell absorb the energy of the light....

Im Focus: The lightest electromagnetic shielding material in the world

Empa researchers have succeeded in applying aerogels to microelectronics: Aerogels based on cellulose nanofibers can effectively shield electromagnetic radiation over a wide frequency range – and they are unrivalled in terms of weight.

Electric motors and electronic devices generate electromagnetic fields that sometimes have to be shielded in order not to affect neighboring electronic...

Im Focus: Gentle wall contact – the right scenario for a fusion power plant

Quasi-continuous power exhaust developed as a wall-friendly method on ASDEX Upgrade

A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

 
Latest News

Porous graphene ribbons doped with nitrogen for electronics and quantum computing

09.07.2020 | Physics and Astronomy

Record efficiency for printed solar cells

09.07.2020 | Power and Electrical Engineering

Rock 'n' control

09.07.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>